Bionomics Announces Early Repayment of Debt

Bionomics Limited (ASX: BNO, OTCQB:BNOEF, Germany: AU000000BNO5) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has prepaid all amounts outstanding of its Debt Obligations to further improve its balance sheet.

"Following our recent successful equity fundraising, full prepayment of our outstanding debt obligations signifies another step in fortifying our balance sheet," said Bionomics' Executive Chairman, Dr Errol De Souza.

Bionomics’ external Debt Obligations accounted for AUD$6,155,674 in combined principal outstanding, consisting of:

- Equipment loan, (at 31 March 2021 the principal amount outstanding was AUD$172,963) with the final monthly repayment due 19 March 2023: and
- Bank loan, denominated in US Dollars, (at 31 March 2021 the principal amount outstanding was AUD$5,982,711) with the final monthly repayment due 1 January 2022.

Early repayment resulted in AUD$98,537 in overall savings to the Company and terminates all commitments and obligations under the loan agreements.

Released on authority of the Board.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8354 6100
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease.

www.bionomics.com.au